Browse the corpus

Chronic bronchitis is a long-term inflammatory condition of the airways, characterized by a persistent productive cough without other identifiable underlying causes lasting at least 3 months per year for 2 consecutive years. In adults, it commonly results from prolonged exposure to lung irritants, with smoking being the primary cause. However, environmental and occupational exposures also contribute. Chronic bronchitis leads to excessive mucus production, causing airway obstruction and inflammation. Symptoms of chronic bronchitis include persistent cough, sputum production, and, in severe cases, shortness of breath, wheezing, and fatigue. While often associated with chronic obstructive pulmonary disease (COPD), it can occur independently, increasing the risk of airflow limitation and lung function decline. In children, chronic bronchitis is typically referred to as protracted bacterial bronchitis (PBB) and is driven by persistent neutrophilic inflammation due to bacterial infections. PBB is defined by a chronic wet cough lasting more than 4 weeks and resolving with a 2-week antibiotic course. If untreated, it may progress to bronchiectasis and long-term lung impairment. This course explores the complexities surrounding chronic bronchitis, including the pathophysiology, risk factors, clinical manifestations across different age groups, the importance of early intervention, and tailored treatment strategies to mitigate long-term complications, improve quality of life, and address the broader health implications, including the heightened risk of cardiovascular events and premature death in young adults with chronic productive coughs. This activity for healthcare professionals is designed to enhance the learner's competence in identifying chronic bronchitis, performing the recommended evaluation, initiating preventive measures, and implementing an appropriate interprofessional approach when managing this condition. Objectives: Identify the key clinical features of chronic bronchitis, including persistent cough, sputum production, and dyspnea. Implement evidence-based pharmacological and nonpharmacological interventions for varying severities of chronic bronchitis. Identify indicated diagnostic studies to evaluate chronic bronchitis. Apply interprofessional team strategies to improve care coordination and patient outcomes for patients with chronic bronchitis.

Identify the key clinical features of chronic bronchitis, including persistent cough, sputum production, and dyspnea. Implement evidence-based pharmacological and nonpharmacological interventions for varying severities of chronic bronchitis. Identify indicated diagnostic studies to evaluate chronic bronchitis. Apply interprofessional team strategies to improve care coordination and patient outcomes for patients with chronic bronchitis. Access free multiple choice questions on this topic.

A persistent cough producing sputum for at least 3 months annually over 2 consecutive years characterizes chronic bronchitis in adults. Goblet cell hyperplasia leads to excessive mucus production. This, combined with reduced mucus clearance, causes airway inflammation, structural changes, and obstruction. Characteristically, chronic bronchitis in children is due to persistent neutrophilic airway inflammation driven by chronic bacterial infection of the airways.[1] For this reason, experts use the term “protracted bacterial bronchitis.”[1] The defining features of protracted bacterial bronchitis (PBB) are an isolated chronic wet cough lasting longer than 4 weeks, resolution with a 2-week course of appropriate antibiotic treatment, and the absence of evidence indicating an alternative cause. Chronic bronchitis in childhood can persist into adulthood, and proper management is imperative as progression to bronchiectasis, asthma, and lung function impairment is possible.[1] In addition, studies reveal that a chronic productive cough in young adults 18 to 30 results in an increased risk of future cardiovascular events and premature deaths, likely due to systemic inflammation.[2] Likewise, childhood asthma and allergies are risk factors for chronic bronchitis in adults. Despite being a common finding in patients with chronic obstructive pulmonary disease (COPD), chronic bronchitis can be an isolated illness with or without airflow obstruction.[3] However, patients with isolated chronic bronchitis are at risk factor for developing airflow obstruction, accelerated lung function decline, COPD exacerbations, and increased lung disease-related and all-cause mortality.[4][5][6] In adults, a strong causal relationship with smoking exists; however, many cases of chronic bronchitis are not associated with smoking, indicating additional risk factors. Hard-rock mining, tunnel work, concrete manufacturing, non-mining industrial work, exposure to biomass fuel burning, and livestock farming are all well-known underlying causes explaining the presence of chronic bronchitis in patients who have never smoked.

Despite being a common finding in patients with chronic obstructive pulmonary disease (COPD), chronic bronchitis can be an isolated illness with or without airflow obstruction.[3] However, patients with isolated chronic bronchitis are at risk factor for developing airflow obstruction, accelerated lung function decline, COPD exacerbations, and increased lung disease-related and all-cause mortality.[4][5][6] In adults, a strong causal relationship with smoking exists; however, many cases of chronic bronchitis are not associated with smoking, indicating additional risk factors. Hard-rock mining, tunnel work, concrete manufacturing, non-mining industrial work, exposure to biomass fuel burning, and livestock farming are all well-known underlying causes explaining the presence of chronic bronchitis in patients who have never smoked. Treatment of chronic bronchitis centers around reducing mucus production, improving mucus clearance, minimizing inflammation, and supporting effective cough mechanisms. Smoking cessation and secondhand smoke avoidance are critical for reducing airway damage and improving respiratory health. Clinicians tailor the management of acute exacerbations based on symptoms with antibiotics, short-acting bronchodilators, and systemic corticosteroids. Patient education regarding self-management and, when available, pulmonary rehabilitation are additional essential management components. Children with PBB require a minimum of 2 weeks of antibiotics, adjusted based on symptom resolution and guideline specifics.[7][8][9] Chronic bronchitis and PBB significantly affect long-term lung function and overall mortality. Healthcare professionals should proactively manage these conditions, utilizing a well-balanced combination of pharmacologic and non-pharmacologic therapies.

Chronic bronchitis results from prolonged exposure to irritants that damage the lungs, with smoking being the primary cause. Among current smokers, the cumulative 30-year incidence is 42%. However, between 4% and 22% of individuals with chronic bronchitis have never smoked, indicating additional contributing factors.[10] Studies show that exposure to gases, mineral dust, fumes, and solvents can lead to chronic bronchitis, even in individuals without COPD.[11][12] Using biomass fuels—such as wood, dung, and crop residues—commonly employed for cooking in rural areas, particularly by women, increases the risk of COPD and chronic bronchitis.[13] Additionally, genetic factors play a role, as evidenced by research linking chronic mucus hypersecretion to a single nucleotide polymorphism on chromosome 3 and identifying a significant genetic locus on chromosome 11p15.5 associated with COPD and chronic bronchitis.[14] Other risk factors include air pollution, asthma, gastroesophageal reflux, recurrent respiratory infections, chronic aspiration, and allergies.[15][16][17] In contrast, chronic infection with nontypeable Haemophilus influenza, Streptococcus pneumoniae, and Moraxella catarrhalis due to impaired mucociliary clearance and airway malacia underlies PBB in children.[18]

Chronic bronchitis is 1 of the most common causes of chronic cough. However, many smokers do not seek care for their cough, and studies regarding chronic cough only reveal a 5% or less incidence of chronic bronchitis.[19] Chronic bronchitis impacts 3% to 22% of the global population and, on average, 27% to 35% of individuals with COPD.[20] In the United States, nearly 10 million people are affected, predominantly between the ages of 44 and 65. Interestingly, 31% of those affected are between 18 and 44.[20] Demographic factors associated with a higher incidence of chronic bronchitis for adults are smoking, older age, increasing COPD severity, female sex, asthma, obstructive sleep apnea, and non-Hispanic Black and White populations.[21][22][23] PBB is the most common cause of wet cough in children younger than 5, accounting for nearly 40% of pediatric pulmonology referrals. PBB is most prevalent in male children 2 and younger, with the median age being 1.8 to 4.8, though PBB is possible in adolescents older than 12.[18][24] Risk factors for developing PBB are childcare attendance, a prior history of chronic cough, parent-reported wheezing in the preceding 12 months, household crowding, and those who are experiencing homelessness.[1][25]

In adults with chronic bronchitis, cigarette smoke exposure, recurrent or chronic viral and bacterial infections, or toxic environmental exposures stimulate mucus overproduction and hypersecretion, and inflammatory and humoral mediators stimulate the release of mucin to protect the airway against noxious stimuli. In addition, inflammatory cells activate the epidermal growth factor receptor (EGFR), which triggers mucin gene transcription. This process leads to the overproduction and hypersecretion of mucus by the increased activation and degranulation of neutrophils due to neutrophil-mediated elastase. EGFR receptor expression and activation are central to mucus hypersecretion, with activated neutrophil involvement being key.[26] In healthy individuals, macrophages clear neutrophils that undergo apoptosis. In patients with COPD or chronic bronchitis, the conditions within the airways foster neutrophil necrosis and release of their intracellular contents, resulting in elevated levels of elastase and reactive oxygen species in the sputum. Activated neutrophils recruited to the airways secrete tumor necrosis factor (TNF)-α, which increases EGFR expression in airway epithelial cells and releases reactive oxygen species that directly activate EGFR. Additionally, neutrophil elastase cleaves the EGFR proligand, pro-transforming growth factor (TGF)-α, releasing mature TGF-α to activate EGFR in a ligand-dependent manner. Neutrophil elastase also induces potent goblet cell degranulation, further contributing to mucus hypersecretion.[27] Experts believe high mucin concentration is the primary culprit of faulty mucus transport and intrapulmonary mucus accumulation. Normal mucus comprises 97% water and 3% solids like mucins, non-mucin proteins, and cellular debris. MUC5AC and MUC5B are 2 mucin polymers that line human airways. MUC5B production significantly increases in patients with chronic bronchitis due to submucosal gland hyperplasia.[28][29] Cigarette smoke, inflammatory cytokines like interleukin-13, air pollutants, viral infections, allergens, and activation of signaling pathways like EGFR increase MUC5AC secretion. Increased sputum MUC5AC in current smokers is associated with increased frequency of exacerbations, increased symptoms, and more significant lung function decline.

Experts believe high mucin concentration is the primary culprit of faulty mucus transport and intrapulmonary mucus accumulation. Normal mucus comprises 97% water and 3% solids like mucins, non-mucin proteins, and cellular debris. MUC5AC and MUC5B are 2 mucin polymers that line human airways. MUC5B production significantly increases in patients with chronic bronchitis due to submucosal gland hyperplasia.[28][29] Cigarette smoke, inflammatory cytokines like interleukin-13, air pollutants, viral infections, allergens, and activation of signaling pathways like EGFR increase MUC5AC secretion. Increased sputum MUC5AC in current smokers is associated with increased frequency of exacerbations, increased symptoms, and more significant lung function decline. Mucous metaplasia obstructs airflow due to mucus hypersecretion and thickening of the epithelial cell layer. In addition, excess mucus alters the airway surface tension, predisposing the airway to expiratory collapse. Inadequate clearing of mucus leads to infection and inflammation of the airways. The presence of chronic cough and sputum production increases the risk of developing COPD regardless of smoking status. Studies reveal that patients younger than 50 with chronic bronchitis and no airflow limitation are at increased risk of developing COPD and all-cause mortality.[30] In children, initial insults, like viral infections or bacterial pneumonia, weaken the lung's defenses, leading to excessive mucus production, reduced mucociliary clearance, and bacterial overgrowth, most likely in a biofilm.[31] A biofilm consists of microbes on the surface encased in an extracellular polymeric substance matrix that supports bacterial persistence and protects bacteria from antibiotics, necessitating prolonged antibiotic treatment. Environmental and genetic factors, including maternal and childhood influences, also play a key role. For instance, exposure to tobacco smoke or air pollution exacerbates airway inflammation and mucosal dysfunction, further promoting bacterial growth.

Gross pathological examination reveals a boggy mucosa characterized by excessive mucinous secretion, pus, and prominent bronchial pits overlying the openings of bronchial mucous glands.Microscopic histological analysis of early chronic bronchitis shows mucus hypersecretion in the large airways, accompanied by hypertrophy of submucosal glands in the trachea and bronchi. As the condition progresses, varying degrees of dysplasia and squamous metaplasia increase goblet cells in the small airways. Submucosal mucous glands progressively occupy a more significant proportion of the bronchial wall, quantified by the Reid index. This index measures the ratio of the mucous gland layer's thickness to the wall thickness between the epithelium and cartilage, with a normal value of <0.4. Patients with chronic bronchitis have an elevated Reid index.[32]

Clinical Features in Adults The most common symptom of chronic bronchitis is a productive cough. Additional symptoms, particularly in patients with COPD, may include dyspnea, wheezing, chest tightness, syncope, fatigue, weight gain resulting from reduced activity due to exertional dyspnea, and weight loss caused by difficulty breathing while eating and the increased metabolic demands of breathing. Patients may also experience depression and anxiety. Sputum is typically clear or white; however, a purulent appearance may indicate a concurrent infection such as acute bronchitis, sinusitis, or bronchiectasis. In patients with COPD, symptoms of chronic bronchitis can occur before or after the onset of airflow limitation. Physical examination findings are typically only present with severe disease or acute exacerbations. Findings associated with mild disease may be faint wheezing or a prolonged expiratory phase. Patients with moderate to severe disease exhibit evidence of hyperinflation, eg, increased resonance to percussion, decreased breath sounds, distant heart sounds, and basilar crackles.[33] Patients with end-stage COPD present with accessory muscle use, inward motion of the lower lateral rib cage on inspiration or Hoover sign, pursed lip breathing, cyanosis, hepatomegaly due to right heart failure, neck vein distension due to increased intrathoracic pressure, and asterixis in the presence of severe hypercapnia.[34] Digital clubbing is not considered a typical finding associated with COPD and suggests an alternative diagnosis like lung cancer, bronchiectasis, or pulmonary fibrosis. Acute exacerbations can range from a mild increase in symptoms to respiratory failure, depending on the baseline respiratory function. Increased cough and sputum production combined with dyspnea, tachycardia, and tachypnea are common findings. Patients with more severe exacerbations and underlying COPD can progress to respiratory failure with acute respiratory acidosis and hypoxemia. Decreased mental status is an indicator of hypoxemia or hypercapnia, and asterixis indicates possible hypercapnia. Clinical Features in Children

Acute exacerbations can range from a mild increase in symptoms to respiratory failure, depending on the baseline respiratory function. Increased cough and sputum production combined with dyspnea, tachycardia, and tachypnea are common findings. Patients with more severe exacerbations and underlying COPD can progress to respiratory failure with acute respiratory acidosis and hypoxemia. Decreased mental status is an indicator of hypoxemia or hypercapnia, and asterixis indicates possible hypercapnia. Clinical Features in Children Children with PBB present with a persistent wet cough of at least 4 weeks. In general, affected children have no evidence of upper respiratory disease like otitis or sinusitis or findings associated with chronic lung disease like digital clubbing or chest wall deformity. Parents may report a history of wheezing, not commonly heard on examination. More often, clinicians auscultate coarse breath sounds or crackles.[18]

Healthcare professionals must begin with a thorough history and physical examination. Clinicians should inquire about fever, night sweats, or weight loss, indicating a possible chronic infection or rheumatic disease. Purulent sputum may indicate a pulmonary or sinus infection, and hemoptysis can indicate cancer, infection, or foreign body aspiration. Dyspnea clues the clinician into airway obstruction or possible parenchymal disease. Patients who are immunosuppressed are at increased risk of infectious causes for their chronic cough, and appropriate investigatory steps must be undertaken. Additionally, the history should include birth and family history, recent choking history, childhood history of asthma or recurrent respiratory illnesses and infections like HIV, tuberculosis, or pneumonia, smoking history, and any exposures to chemicals, dust, fumes, or biomass fuels. In addition, clinicians should inquire about medications that may cause cough. Patients on angiotensin-converting enzyme inhibitors should undergo a 4-week trial of discontinuing the medication before undergoing an extensive evaluation. In addition, clinicians must consider medications like bisphosphonates and calcium channel blockers that can worsen gastroesophageal reflux disease. A cough that exceeds 8 weeks in an adult and 4 weeks in children warrants a chest radiograph except in patients with asthma and those with upper airway cough syndrome due to postnasal drip, acute sinusitis, vasomotor, or allergic rhinitis.[7] Further imaging with computed tomography (CT) of the chest evaluates abnormalities on chest radiographs or becomes necessary when an elevated suspicion for abnormalities like lung cancer exists in the presence of a normal chest radiograph. Pulmonary function tests, including prebronchodilator and postbronchodilator measurements, assess for COPD and asthma in children 3 and older and adults.[7][35] The diagnosis of PBB is primarily clinical and based on the following criteria: Chronic wet cough for at least 4 weeks No evidence of alternative diagnoses following evaluation, including normal spirometry and chest radiography (peribronchial accentuation on chest radiography is acceptable) No signs or symptoms of alternative diagnoses Cough resolution after 2 weeks of appropriate antibiotics [36]

The diagnosis of PBB is primarily clinical and based on the following criteria: Chronic wet cough for at least 4 weeks No evidence of alternative diagnoses following evaluation, including normal spirometry and chest radiography (peribronchial accentuation on chest radiography is acceptable) No signs or symptoms of alternative diagnoses Cough resolution after 2 weeks of appropriate antibiotics [36] Bronchoscopy is unnecessary to establish the diagnosis of PBB unless the patient presents with atypical features or suspicion of an inhaled foreign body. Some clinicians choose to perform bronchoscopy with bronchoalveolar lavage (BAL) and cultures to guide antibiotic choice, especially in children with a prolonged cough or those who fail initial antibiotic treatment. Children with more than 3 episodes of PBB per year warrant further evaluation for underlying causes that predispose them to infections. Evaluation includes bronchoscopy with BAL, potentially a high-resolution CT scan of the chest, sweat test, and evaluation of the immune system.[37]

Chronic Bronchitis Management The primary objectives in treating chronic bronchitis are to reduce excessive mucus production, decrease mucus hypersecretion by minimizing inflammation, enhance ciliary transport for better mucus clearance, lower mucus viscosity, and support effective cough mechanisms. Effective management is crucial due to the association between chronic bronchitis, PBB, long-term respiratory health, and overall mortality. The cornerstone of chronic bronchitis treatment is smoking cessation and minimizing exposure to harmful environmental factors. Quitting smoking and avoiding secondhand smoke significantly improve mucociliary function, reduce airway damage, and decrease goblet cell hyperplasia.[38] A 30-year longitudinal study indicates that the cumulative incidence of chronic bronchitis is 42% in current smokers, 26% in former smokers, and 22% in individuals who have never smoked.[10] Guidelines and opinions differ regarding mucolytics like N-acetylcysteine, carbocysteine, and erdosteine, which reduce mucus overproduction and enhance its clearance. The American Academy of Chest Physicians advises against mucolytics, bronchodilators, or antibiotics for managing chronic cough in patients with stable chronic bronchitis.[39] They also do not recommend nonpharmacologic interventions such as positive end-expiratory pressure.[39] Conversely, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines suggest that mucolytics can reduce exacerbation frequency by approximately 1 episode every 3 years. GOLD supports their routine use for a modest reduction in acute exacerbations and improvement in quality of life.

Guidelines and opinions differ regarding mucolytics like N-acetylcysteine, carbocysteine, and erdosteine, which reduce mucus overproduction and enhance its clearance. The American Academy of Chest Physicians advises against mucolytics, bronchodilators, or antibiotics for managing chronic cough in patients with stable chronic bronchitis.[39] They also do not recommend nonpharmacologic interventions such as positive end-expiratory pressure.[39] Conversely, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines suggest that mucolytics can reduce exacerbation frequency by approximately 1 episode every 3 years. GOLD supports their routine use for a modest reduction in acute exacerbations and improvement in quality of life. The mainstay of therapy for acute exacerbations is short-acting bronchodilators like albuterol, dosed with a nebulizer or metered dose inhaler (MDI) every 20 minutes for 2 to 3 doses, then every 2 to 4 hours as needed. Both are equally efficacious, but patients with severe COPD or who struggle with MDI use may find increased relief with the nebulized form. Clinicians can combine albuterol with the anticholinergic bronchodilator ipratropium bromide if necessary. Ipratropium, dosed every 4 to 6 hours, is not generally used alone during an acute exacerbation, given its prolonged onset of action. Patients with moderate to severe symptoms should also receive systemic steroids equivalent to 40 mg of prednisone daily for 5 days. Acute exacerbations warrant antibiotics if the patient exhibits 3 of the following cardinal symptoms: increased dyspnea, sputum volume, and sputum purulence.[40][41] Antibiotics are also appropriate if 2 of the cardinal symptoms are present, and 1 is sputum purulence. Antibiotic therapy The choice of antibiotic depends on local resistance patterns, patient risk factors, and risk of chronic Pseudomonas infection. The following recommendations should be considered for each of these factors: Average risk patients: Clinicians choose either a macrolide or second- or third-generation cephalosporin, like cefuroxime or cefpodoxime, for patients without risk factors for poor outcomes or Pseudomonas colonization. High risk patients: Clinicians should choose either amoxicillin-clavulanic acid or a respiratory quinolone like levofloxacin or moxifloxacin for patients with the following features: Age 65 and older

Average risk patients: Clinicians choose either a macrolide or second- or third-generation cephalosporin, like cefuroxime or cefpodoxime, for patients without risk factors for poor outcomes or Pseudomonas colonization. High risk patients: Clinicians should choose either amoxicillin-clavulanic acid or a respiratory quinolone like levofloxacin or moxifloxacin for patients with the following features: Age 65 and older Two or more COPD exacerbations in the previous 12 months One or more COPD-related hospitalizations in the previous 12 months FEV1 <50% predicted Comorbid conditions like heart failure or ischemic heart disease Continuous supplemental oxygen [42][43][44] Pseudomonas infection: Ciprofloxacin plus sputum cultures are appropriate for patients with an increased risk of Pseudomonas colonization. Patients at risk of Pseudomonas colonization are those with a known history of Pseudomonas colonization or sputum culture revealing Pseudomonas within the previous 12 months or patients with risk factors for poor outcomes and the following features: FEV1 <30% predicted Bronchiectasis on chest computed tomography (CT) scan Broad-spectrum antibiotic use within the previous 3 months Chronic systemic corticosteroid use According to the GOLD guidelines, antibiotic therapy should continue for 5 days, with reassessment at the end of therapy. Prolonged therapy does not provide additional benefits in most patients.[40][41][45][46] Other management considerations Phosphodiesterase-4 (PDE-4) inhibitors like roflumilast can reduce exacerbations in patients with severe COPD and chronic bronchitis who have a history of exacerbations by decreasing inflammation and promoting airway smooth muscle relaxation. They prevent the hydrolysis of cyclic adenosine monophosphate, a substance that, when degraded, releases inflammatory mediators. The GOLD guidelines recommend clinicians consider adding roflumilast in patients with COPD and chronic bronchitis who have a forced expiratory volume in 1 second less than 50% predicted and who have had at least 1 hospitalization for an exacerbation in the past 12 months.

Phosphodiesterase-4 (PDE-4) inhibitors like roflumilast can reduce exacerbations in patients with severe COPD and chronic bronchitis who have a history of exacerbations by decreasing inflammation and promoting airway smooth muscle relaxation. They prevent the hydrolysis of cyclic adenosine monophosphate, a substance that, when degraded, releases inflammatory mediators. The GOLD guidelines recommend clinicians consider adding roflumilast in patients with COPD and chronic bronchitis who have a forced expiratory volume in 1 second less than 50% predicted and who have had at least 1 hospitalization for an exacerbation in the past 12 months. Pulmonary rehabilitation for a minimum of 6 weeks is an important component of treating chronic bronchitis. Effective pulmonary rehabilitation includes supervised exercise training at least twice weekly, self-management education, and psychosocial support. Pulmonary rehabilitation improves exercise tolerance, shortness of breath, and overall health status while reducing hospitalizations in patients with frequent exacerbations. Patients who undergo pulmonary rehabilitation also report reduced feelings of depression and anxiety.[47][48] Cost and access are barriers to participation in pulmonary rehabilitation for many patients. Protracted Bacterial Bronchitis American and European guidelines suggest treating children with PBB with a minimum of 2 weeks of antibiotic therapy followed by an additional 2 weeks if the cough does not resolve at the end of the initial period.[7][8] The British Thoracic Society guidelines treat all children with 4 to 6 weeks of antibiotics.[9] Amoxicillin-clavulanate is typically the first-line treatment. Acceptable alternatives are oral second- or third-generation cephalosporins, trimethoprim-sulfamethoxazole, or a macrolide except for azithromycin due to increasing Streptococcus pneumoniae and Haemophilus influenzae resistance. Children who experience more than 3 episodes of PBB in 1 year should undergo evaluation for bronchiectasis, chronic suppurative lung disease, or an underlying lung disease that predisposes them to recurrent infection. Clinicians should consider a retained foreign body, cystic fibrosis, primary ciliary dyskinesia, and immunodeficiency. Affected children should undergo bronchoscopy with BAL, sweat test, chest CT scan, and immune evaluation. Vaccine Recommendations

American and European guidelines suggest treating children with PBB with a minimum of 2 weeks of antibiotic therapy followed by an additional 2 weeks if the cough does not resolve at the end of the initial period.[7][8] The British Thoracic Society guidelines treat all children with 4 to 6 weeks of antibiotics.[9] Amoxicillin-clavulanate is typically the first-line treatment. Acceptable alternatives are oral second- or third-generation cephalosporins, trimethoprim-sulfamethoxazole, or a macrolide except for azithromycin due to increasing Streptococcus pneumoniae and Haemophilus influenzae resistance. Children who experience more than 3 episodes of PBB in 1 year should undergo evaluation for bronchiectasis, chronic suppurative lung disease, or an underlying lung disease that predisposes them to recurrent infection. Clinicians should consider a retained foreign body, cystic fibrosis, primary ciliary dyskinesia, and immunodeficiency. Affected children should undergo bronchoscopy with BAL, sweat test, chest CT scan, and immune evaluation. Vaccine Recommendations Current guidelines recommend multiple vaccines for patients with chronic lung disease, including: Patients should receive an annual influenza vaccination. The 21-valent pneumococcal conjugate (PCV21) alone, 20-valent PCV20 alone, or 15-valent PCV15 followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults 19 and older with chronic lung disease. PCV21 is the preferred formulation in adult patients except those at increased risk of serotype 4. PCV20 provides coverage for serotype 4 and is the vaccine of choice for residents of the Navajo Nation or individuals living in the Western United States and Canada who have substance use disorder or are experiencing homelessness. Those who previously received only the PPSV23, PPV10, or PPV13 should receive PPV21 or PPV20 at least 1 year after receiving PPSV23. Healthcare professionals can access the most recent pneumococcal vaccine guidelines, including revaccination recommendations, at the United States Centers for Disease Control's website.[49] The Covid-19 vaccine should be administered. Tetanus, diphtheria, and pertussis vaccine (Tdap) should be administered based on the routine adult schedule. Individuals older than 60 or with chronic heart or lung disease should receive the respiratory syncytial virus vaccine.

The 21-valent pneumococcal conjugate (PCV21) alone, 20-valent PCV20 alone, or 15-valent PCV15 followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults 19 and older with chronic lung disease. PCV21 is the preferred formulation in adult patients except those at increased risk of serotype 4. PCV20 provides coverage for serotype 4 and is the vaccine of choice for residents of the Navajo Nation or individuals living in the Western United States and Canada who have substance use disorder or are experiencing homelessness. Those who previously received only the PPSV23, PPV10, or PPV13 should receive PPV21 or PPV20 at least 1 year after receiving PPSV23. Healthcare professionals can access the most recent pneumococcal vaccine guidelines, including revaccination recommendations, at the United States Centers for Disease Control's website.[49] The Covid-19 vaccine should be administered. Tetanus, diphtheria, and pertussis vaccine (Tdap) should be administered based on the routine adult schedule. Individuals older than 60 or with chronic heart or lung disease should receive the respiratory syncytial virus vaccine. Patients with COPD aged 50 and older should receive the herpes zoster vaccine.[50][51][52]

When evaluating chronic bronchitis, other differential diagnoses that should be considered include: Acute bronchitis Acute sinusitis Alpha-1 antitrypsin (ATT) deficiency Asthma Bacterial pharyngitis Bronchiectasis Bronchiolitis Bronchomalacia Chronic sinusitis Chronic suppurative lung disease COPD Cystic fibrosis Diffuse panbronchiolitis Endemic fungal and parasitic infections Gastroesophageal reflux disease Immunodeficiency Influenza Lung cancer Medication effects Obstruction or anatomic abnormality in the airway Obstructive sleep apnea Pertussis Pneumonia Postinfectious cough Primary ciliary dyskinesia Pulmonary fibrosis Heart failure Tracheomalacia Tuberculosis Upper airway cough syndrome [18][53][54][55]

Current areas of investigation involve bronchoscopic techniques to eliminate mucus hypersecretion by eliminating goblet cell hyperplasia. Techniques currently under investigation are liquid nitrogen metered cryo spray, rheoplasty, and targeted lung denervation.[56] Rheoplasty uses nonthermal pulsed electrical fields to ablate abnormal mucus-producing cells. This process allows the regeneration of healthy epithelium. In addition, a phase 3 randomized trial of 939 patients with COPD, chronic bronchitis, and a baseline blood eosinophil count greater than 300 cells/μL reveals that the interleukin-4 receptor alpha antagonist, dupilumab, reduces exacerbations by 34%. Dupilumab also reduces respiratory symptom severity, improves FEV1, and quality of life when compared to placebo. However, dupilumab has not yet been approved by the US Food and Drug Administration for this application.[57]

Chronic bronchitis significantly impacts lung function and increases the risk of mortality, being linked to worsening airflow obstruction, declining lung function, and higher all-cause mortality, particularly in patients younger than 50, including patients who have never smoked.[30] Some experts suggest the increased risk of all-cause mortality may be due to systemic inflammation marked by increased levels of serum interleukin-8 and C-reactive protein found in patients with chronic bronchitis. Factors that affect the overall prognosis are the severity of the disease, age, genetics, smoking history, concurrent health conditions, and overall access to healthcare. Patients with chronic bronchitis symptoms have a 2-fold increased risk of developing new airflow obstruction compared to the asymptomatic population, and 50% of smokers with chronic bronchitis will develop COPD.[58] Chronic bronchitis also leads to a lessened quality of life and double the number of COPD-related hospital days compared to patients without chronic bronchitis.[48][59] Decreasing cigarette consumption can increase lifespan by nearly 2.4 years.[10] The overall prognosis of PBB is good. However, if left untreated, patients can develop bronchiectasis, which can lead to significant morbidity and mortality.[60] A 5-year follow-up study of children with PBB reveals that two-thirds remain symptomatic, and nearly 10% have bronchiectasis, reinforcing the importance of careful follow-up and involving a pulmonary specialist in the healthcare team.[61]

In addition to worsening lung function, development of COPD, and all-cause mortality, chronic bronchitis may cause additional complications including: Anxiety and depression Asthma Bronchiectasis COPD Cor pulmonale Death Dyspnea Hemoptysis Increased risk of cardiac disease Increased susceptibility to respiratory infections like influenza, pneumonia, and the common cold Osteoporosis due to immobility and corticosteroid use Pneumothorax Polycythemia Pulmonary hypertension [62]

Chronic bronchitis and PBB have profound effects on future lung function and all-cause mortality. Early identification, diagnosis, and patient education are crucial in managing both conditions. Clinicians must focus on preventing disease progression and empowering patients to take control of their lung health. Healthcare professionals play a vital role in helping patients understand the complications of chronic bronchitis and PBB. Clinicians must provide proper education on the risks associated with smoking—the leading cause of chronic bronchitis—and provide appropriate counseling and support to aid in smoking cessation. In addition, patients must avoid environments with secondhand smoke and recognize environmental causes, including work, chemical, and biomass fuel exposures. Encouraging a healthy lifestyle is essential. Clinicians should encourage patients to maintain a balanced diet, exercise regularly within their physical limits, and stay hydrated to support overall lung function. Patients should also be encouraged to participate in pulmonary rehabilitation programs. These programs provide structured education, breathing exercises, and tailored physical training, improving lung function and quality of life. Medication adherence is another cornerstone of management. Clinicians should stress the importance of using prescribed medications, including inhalers or systemic glucocorticoids while teaching correct inhaler techniques to ensure effective medication delivery. Patients benefit from learning to recognize early symptoms of an exacerbation (eg, increased coughing, mucus production, and shortness of breath) and seeking prompt medical care. By equipping individuals with knowledge and practical tools, clinicians empower them to manage their condition actively, reducing the likelihood of disease progression and complications. Early intervention, supported by comprehensive patient education, is pivotal in promoting long-term lung health and enhancing the quality of life for those living with chronic bronchitis.

Managing chronic bronchitis requires a comprehensive, interprofessional approach that integrates the expertise of various healthcare professionals, including pulmonary specialists, primary care clinicians, emergency and cardiology clinicians, pharmacists, respiratory therapists, nurses, physical therapists, and dieticians to optimize patient-centered care by balancing interventions to improve patient outcomes, enhance safety, and support long-term disease management. Physicians and advanced practitioners play a critical role in diagnosing chronic bronchitis, ordering necessary diagnostic tests, prescribing appropriate treatments, and ensuring patients receive recommended vaccinations. Nurses provide essential patient education on smoking cessation, proper inhaler techniques, and vaccine administration while serving as key communication facilitators between healthcare team members. Physical therapists support pulmonary rehabilitation efforts by promoting physical activity to maintain lung function and overall well-being, while dieticians help prevent respiratory cachexia by guiding patients toward a well-balanced diet tailored to their specific needs. Pharmacists contribute by ensuring appropriate medication selection, educating patients on proper usage, and monitoring for potential adverse effects or drug interactions.

Managing chronic bronchitis requires a comprehensive, interprofessional approach that integrates the expertise of various healthcare professionals, including pulmonary specialists, primary care clinicians, emergency and cardiology clinicians, pharmacists, respiratory therapists, nurses, physical therapists, and dieticians to optimize patient-centered care by balancing interventions to improve patient outcomes, enhance safety, and support long-term disease management. Physicians and advanced practitioners play a critical role in diagnosing chronic bronchitis, ordering necessary diagnostic tests, prescribing appropriate treatments, and ensuring patients receive recommended vaccinations. Nurses provide essential patient education on smoking cessation, proper inhaler techniques, and vaccine administration while serving as key communication facilitators between healthcare team members. Physical therapists support pulmonary rehabilitation efforts by promoting physical activity to maintain lung function and overall well-being, while dieticians help prevent respiratory cachexia by guiding patients toward a well-balanced diet tailored to their specific needs. Pharmacists contribute by ensuring appropriate medication selection, educating patients on proper usage, and monitoring for potential adverse effects or drug interactions. Effective interprofessional communication is crucial in coordinating care, addressing the multiple morbidities associated with chronic bronchitis, and ensuring that treatment strategies are seamlessly implemented. By fostering collaboration, healthcare professionals can develop individualized treatment plans that address both the underlying causes and symptoms of chronic bronchitis while considering each patient's unique health status and comorbid conditions. Care coordination between healthcare team members is essential to reduce hospitalizations, prevent disease progression, and enhance overall quality of life. Regular follow-ups, remote monitoring, and patient self-management education empower patients to participate actively in their treatment. An interprofessional team also ensures that acute exacerbations are promptly managed, reducing complications and improving long-term outcomes. By leveraging their specialized skills, fostering seamless communication, and prioritizing coordinated care, healthcare professionals can enhance patient-centered care, improve clinical outcomes, and optimize team performance in the management of chronic bronchitis.